Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

Jung, Minkyu; Kim, Se Hyun; Lee, Young Joo; Hong, Soojung; Kang, Young Ae; Kim, Se Kyu; Chang, Joon; Rha, Sun Young; Kim, Joo Hang; Kim, Dae Joon; Cho, Byoung Chul

doi:10.3892/etm.2011.273

Cited by 31 publications

(34 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has also been a report suggesting that serum CYFRA 21–1 levels might serve as a prognostic factor in patients with recurrent NSCLC receiving 3 rd -line or later gefitinib therapy [30]. Some studies have suggested the possible prognostic value of pretreatment serum CYFRA 21–1 values (PCV) in patients with surgically treated lung adenocarcinoma [31] and advanced NSCLC [32-34]. However, none of the studies suggesting serum CYFRA 21–1 as a prognostic factor in patients with untreated advanced lung adenocarcinoma has included the EGFR mutation status as a variable.…”

Section: Introductionmentioning

confidence: 99%

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

et al. 2013

View full text Add to dashboard Cite

BackgroundSerum CYFRA 21–1 is one of the most important serum markers in the diagnosis of non-small cell lung cancer (NSCLC), especially squamous-cell carcinoma. However, it remains unknown whether pretreatment serum CYFRA 21–1 values (PCV) may also have prognostic implications in patients with advanced lung adenocarcinoma.MethodsWe retrospectively reviewed the data of 284 patients (pts) who were diagnosed as having advanced lung adenocarcinoma and had received initial therapy.ResultsOf the study subjects, 121 pts (43%) had activating epidermal growth factor receptor (EGFR) mutations (Mt+), while the remaining 163 pts (57%) had wild-type EGFR (Mt-). Univariate analysis identified gender (male/ female), ECOG performance status (PS) (0-1/ ≥2), PCV (<2.2 ng/ml/ ≥2.2 ng/ml), EGFR mutation status (Mt+/ Mt-), pretreatment serum CEA values (<5.0 ng/ml/ ≥5.0 ng/ml), smoking history (yes/ no) and EGFR-TKI treatment (yes/ no) as prognostic factors (p = .008, p < .0001, p < .0001, p < .0001, p = .036, p = .0012, p < .0001 respectively). Cox's multivariate regression analysis identified PCV < 2.2ng/ml as the only factor significantly associated with prolonged survival (p < .0001, hazard ratio: 0.43, 95% CI 0.31-0.59), after adjustments for PS (p < .0001), EGFR mutation status (p = .0069), date of start of initial therapy (p = .07), gender (p = .75), serum CEA level (p = .63), smoking history (p = .39) and EGFR-TKI treatment (p = .20). Furthermore, pts with Mt+ and PCV of <2.2 ng/ml had a more favorable prognosis than those with Mt+ and PCV of ≥2.2 ng/ml (MST: 67.0 vs. 21.0 months, p < .0001), and patients with Mt- and PCV of <2.2 ng/ml had a more favorable prognosis than those with Mt- and PCV of ≥2.2 ng/ml (MST: 24.1 vs. 10.2 months, p < .0001).ConclusionPCV may be a potential independent prognostic factor in both Mt+ and Mt- patients with advanced lung adenocarcinoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

et al. 2013

View full text Add to dashboard Cite

show abstract

“…CK19 has been reported to be over-expressed in many lung cancer tissue specimens (11,12), which results in an increase of the plasma CYFRA21-1 values (13). Some studies reported that CYFRA21-1 can be useful for pathological typing and assessment of treatment efficacy of NSCLC (14,15).…”

Section: Introductionmentioning

confidence: 99%

Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study

et al. 2016

View full text Add to dashboard Cite

“…10 It is estimated that 8-15% of patients with lung cancer have MPE, with higher frequencies observed in those with lung adenocarcinoma, 11 but the mechanism and genetic or epigenetic changes involved in MPE formation are not well understood.…”

Section: Introductionmentioning

confidence: 99%

Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation

et al. 2014

View full text Add to dashboard Cite

Objective: A retrospective single-centre study to compare the clinical features of patients with lung adenocarcinoma with and without epidermal growth factor receptor (EGFR) mutations. Methods: Pretreatment medical records of patients with lung adenocarcinoma were reviewed. DNA was extracted from paraffin wax-embedded tumour tissue for analysis of EGFR mutations. Malignant pleural effusion (MPE) was diagnosed by cytopathological testing of pleural fluid. Results: EGFR mutations (19-Del and L858R) were recorded in 81/283 patients (28.6%). MPE was found in 42/283 patients (14.8%). In patients with stage IV disease, the frequency of EGFR mutations was higher in those with MPE than in those without MPE. EGFR mutations were independently associated with female sex, no history of smoking and presence of MPE. Conclusions: There was a positive association between EGFR mutation and the presence of MPE. EGFR mutations may play an important role in the formation of MPE.

show abstract

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

Cited by 31 publications

References 31 publications

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study

Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation

Contact Info

Product

Resources

About